Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia

British Journal of Pharmacology

Volumn 146, Issue 4, 2005, Pages 568-575

  Bellik, Lydia ^a   Vinci, Maria Cristina ^a   Filippi, Sandra ^a   Ledda, Fabrizio ^a   Parenti, Astrid ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

fms like tyrosine kinase (Flt 1); Hypoxia; p38; Placental growth factor (PlGF); STAT3; Vascular smooth muscle cell (VSMC) proliferation; Vascular tone

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACENTAL GROWTH FACTOR; PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; AORTA; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HYPOXIA; MALE; MUSCLE FIBER CONTRACTION; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; AORTA, THORACIC; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; MALE; MORPHOLINES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PREGNANCY PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TYRPHOSTINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASOCONSTRICTION;

EID: 27144513291     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706347     Document Type: Article

References (42)

1. AMERINI, S., FILIPPI, S., PARENTI, A., LEDDA, F. & ZICHE, M. (1997). Vasorelaxant effect induced by the angiogenic drug Linomide in aortic and saphenous vein preparations of the rabbit. Br. J. Pharmacol., 122, 1739-1745.
2. AUTIERO, M., WALTENBERGER, J., COMMUNI, D., KRANZ, A., MOONS, L., LAMBRECHTS, D., KROLL, J., PLAISANCE, S., DE MOL, M., BONO, F., KLICHE, S., FELLBRICH, G., BALLMERHOFER, K., MAGLIONE, D., MAYR-BEYRLE, U., DEWERCHIN, M., DOMBROWSKI, S., STANIMIROVIC, D., VAN HUMMELEN, P., DEHIO, C., HICKLIN, D.J., PERSICO, G., HERBERT, J.M., COMMUNI, D., SHIBUYA, M., COLLEN, D., CONWAY, E.M. & CARMELIET, P. (2003). Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med., 9, 936-943.
3. BARLEON, B., SOZZANI, S., ZHOU, D., WEICH, H.A., MANTOVANI, A. & MARM, D. (1996). Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor VEGFR-1. Blood, 87, 3336-3343.
4. 1/2 and p38 MAP kinase in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun., 296, 890-896.
5. BUSCHMANN, I. & SCHAPER, W. (2000). The pathophysiology of the collateral circulation (arteriogenesis). J. Pathol., 190, 338-342.
6. CARMELIET, P., MOONS, L., LUTTUN, A., VINCENTI, V., COMPERNOLLE, V., DE MOL, M., WU, Y., BONO, F., DEVY, L., BECK, H., SCHOLZ, D., ACKER, T., DIPALMA, T., DEWERCHIN, M., NOEL, A., STALMANS, I., BARRA, A., BLACHER, S., VANDENDRIESSCHE, T., PONTEN, A., ERIKSSON, U., PLATE, K.H., FOIDART, J.M., SCHAPER, W., CHARNOCK-JONES, D.S., HICKLIN, D.J., HERBERT, J.M., COLLEN, D. & PERSICO, M.G. (2001). Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med., 7, 575-583.
7. CAUDILL, T.K., RESTA, T.C., KANAGY, N.L. & WALKER, B.R. (1998). Role of endothelial carbon monoxide in attenuated vasoreactivity following chronic hypoxia. Am. J. Physiol., 275, R1025-R1030.
8. CERESA, B.P., HORVATH, C.M. & PESSIN, J.E. (1997). Signal transducer and activator of transcription-3 serine phosphorylation by insulin is mediated by a Ras/Raf/MEK-dependent pathway. Endocrinology, 138, 4131-4137.
9. CHUNG, J., UCHIDA, E., GRAMMER, T.C. & BLENIS, J. (1997). STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol., 17, 6508-6516.
10. CICCONI, S., VENTURA, N., PASTORE, D., BONINI, P., DI NARDO, P., LAURO, R. & MARLIER, L.N. (2003). Characterization of apoptosis signal transduction pathways in HL-5 cardiomyocytes exposed to ischemia/reperfusion oxidative stress model. J. Cell. Physiol., 195, 27-37.
11. COUPER, L.L., BRYANT, S.R., ELDRUP-JØRGENSEN, J., BREDENBERG, C.E. & LINDNER, V. (1997). Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1. Circ. Res., 81, 932-939.
12. DE VRIES, C., ESCOBEDO, J.A., UENO, H., HOUCK, K., FERRARA, N. & WILLIAMS, L.T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-991.
13. DOUGHER, M. & TERMAN, B.I. (1999). Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene, 18, 1619-1627.
14. FEISTRITZER, C., KANEIDER, N.C., STURN, D.H., MOSHEIMER, B.A., KAHLER, C.M. & WIEDERMANN, C.J. (2004). Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am. J. Resp. Cell. Mol. Biol., 30, 729-735.
15. FERRARA, N., GERBER, H.P. & LECOUTER, J. (2003). The biology of VEGF and its receptors. Nat. Med., 9, 669-676.
16. GERBER, H.P., CONDORELLI, F., PARK, J. & FERRARA, N. (1997). Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. VEGFR-1, but not Flk-1/KDR, is upregulated by hypoxia. J. Biol. Chem., 272, 23659-23667.
17. GERBER, H.P. & FERRARA, N. (2003). The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med., 81, 20-31.
18. HAN, J., LEE, J.D., BIBBS, L. & ULEVITCH, R.J. (1994). A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 265, 808-811.
19. JAIN, N., ZHANG, T., FONG, S.L., LIM, C.P. & CAO, X. (1998). Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene, 17, 3157-3167.
20. KALYANKRISHNA, S. & MALIK, K.U. (2003). Norepinephrine-induced stimulation of p38 mitogen-activated protein kinase is mediated by arachidonic acid metabolites generated by activation of cytosolic phospholipase A(2) in vascular smooth muscle cells. J. Pharmacol. Exp. Ther., 304, 761-772.
21. KATAYOSE, D., OHE, M., YAMAUCHI, K., OGATA, M., SHIRATO, K., FUJITA, H., SHIBAHARA, S. & TAKISHIMA, T. (1993). Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am. J. Physiol., 264, L100-L106.
22. LADOUX, A. & FRELIN, C. (1993). Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem. Biophys. Res. Commun., 195, 1005-1010.
23. LANDGREN, E., SCHILLER, P., CAO, Y. & CLAESSON-WELSH, L. (1998). Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene, 16, 359-367.
24. LIM, C.P. & CAO, X. (2001). Regulation of Stat3 activation by MEK kinase 1. J. Biol. Chem., 276, 21004-21011.
25. MADAMANCHI, N.R., LI, S., PATTERSON, C. & RUNGE, M.S. (2001). Thrombin regulates vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway. J. Biol. Chem., 276, 18915-18924.
26. MAZIERE, C., ALIMARDANI, G., DANTIN, F., DUBOIS, F., CONTE, M.A. & MAZIERE, J.C. (1999). Oxidized LDL activates STAT1 and STAT3 transcription factors: possible involvement of reactive oxygen species. FEBS Lett., 448, 49-52.
27. NEELI, I., LIU, Z., DRONADULA, N., MA, Z.A. & RAO, G.N. (2004). An essential role of the Jak-2/STAT-3/cytosolic phospholipase A2 axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility. J. Biol. Chem., 279, 46122-46128.
28. NEUFELD, G., COHEN, T., GENGRINOVITCH, S. & POLTORAK, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13, 9-22.
29. PARENTI, A., BROGELLI, L., DONNINI, S., ZICHE, M. & LEDDA, F. (2001). Angiotensin II potentiates the mitogenic effect of noradrenaline in vascular smooth muscle cells: role of FGF-2. Am. J. Physiol., 280, H99-H107.
30. PARENTI, A., BROGELLI, L., FILIPPI, S., DONNINI, S. & LEDDA, L. (2002). Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF: role of Flt-1/VEGF-receptor-1. Cardiovasc. Res., 55, 201-212.
31. PARK, J.E., CHEN, H.H., WINER, J., HOUCK, K.A. & FERRARA, N. (1994). Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem., 269, 25646-25654.
32. RAKUGI, H., TABUCHI, Y., NAKAMARU, M., NAGANO, M., HIGASHIMORI, K., MIKAMI, H., OGIHARA, T. & SUZUKI, N. (1990). Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem. Biophys. Res. Commun., 169, 973-977.
33. RAJ, U. & SHIMODA, L. (2002). Oxygen-dependent signaling in pulmonary vascular smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol., 283, L671-L677.
34. SAMBUCETI, G., MARZILLI, M., MARRACCINI, P., SCHNEIDEREICKE, J., GLIOZHENI, E., PARODI, O. & L'ABBATE, A. (1997). Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation, 95, 2652-2659.
35. SCHRATZBERGER, P., SCHRATZBERGER, G., SILVER, M., CURRY, C., KEARNEY, M., MAGNER, M., ALROY, J., ADELMAN, L.S., WEINBERG, D.H., ROPPER, A.H. & ISNER, J.M. (2000). Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med., 6, 405-413.
36. SEKI, Y., KAI, H., SHIBATA, R., NAGATA, T., YASUKAWA, H., YOSHIMURA, A. & IMAIZUMI, T. (2000). Role of the JAK/STAT pathway in rat carotid artery remodelling after vascular injury. Circ. Res., 87, 12-18.
37. SHIBUYA, M. (2001). Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int. J. Biochem. Cell Biol., 33, 409-420.
38. SIMMONS, J.G., PUCILOWSKA, J.B. & LUND, P.K. (1999). Autocrine and paracrine actions of intestinal fibroblast-derived insulin-like growth factors. Am. J. Physiol., 276, G817-G827.
39. YAMAWAKI, H., LEHOUX, S. & BERK, B.C. (2003). Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation, 108, 1619-1625.
40. WANG, H. & KEISER, J.A. (1998). Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ. Res., 83, 832-840.
41. WATANABE, S., MU, W., KAHN, A., JING, N., LI, J.H., LAN, H.Y., NAKAGAWA, T., OHASHI, R. & JOHNSON, R.J. (2004). Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells. Am. J. Nephrol., 24, 387-392.
42. WEN, Z., ZHONG, Z. & DARNELL JR, J.E. (1995). Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 82, 241-250.